Despite the lack of scientific advancements since the first SSRI hit the market in the late 1980s, novel antidepressants are beginning to see the light of day - Ashley Chiara PharmD
image by: Cranimals
Aside from developing novel mechanisms, drug developers are getting creative by combining existing antidepressants with other chemical entities to build off the benefits of current therapies...
Possibly the most streamlined approach being taken by drug developers is utilizing existing therapies for other indications and exploring their effectiveness for treating depression...
Taking creativity and ingenuity a step further, entities classically known as psychedelics are being explored for their antidepressant effects. Most notably, the serotonergic and glutaminergic properties of the hallucinogen psilocybin have been studied in small clinical trials of patients with MDD.